Metethoheptazine[1] (WY-535) is an opioid analgesic from the phenazepine family. It was invented in the 1960s.[2]

Metethoheptazine
Clinical data
Other namesWY-535
ATC code
  • none
Identifiers
  • ethyl 1,3-dimethyl-4-phenylazepane-4-carboxylate
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC17H25NO2
Molar mass275.392 g·mol−1
3D model (JSmol)
  • O=C(OCC)C2(c1ccccc1)CCCN(C)CC2C
  • InChI=1S/C17H25NO2/c1-4-20-16(19)17(15-9-6-5-7-10-15)11-8-12-18(3)13-14(17)2/h5-7,9-10,14H,4,8,11-13H2,1-3H3 checkY
  • Key:BOSULDNQDJLKKL-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Metethoheptazine produces similar effects to other opioids, including analgesia, sedation, dizziness and nausea.

Metethoheptazine is not listed as a controlled substance under the Controlled Substances Act 1970 in the United States.[3] The Canadian Controlled Drugs and Substances Act specifically excludes the phenazepine opioids from control.

References

edit
  1. ^ GB 843924, "Substituted azacycloheptanes", assigned to American Home Products 
  2. ^ Walkenstein SS, Corradino RA, Wiser R, Gudmundsen CH (February 1965). "Metabolism of the Non-Narcotic Analgesic, WY-5355". Biochemical Pharmacology. 14 (2): 121–8. doi:10.1016/0006-2952(65)90067-5. PMID 14332457.
  3. ^ "Conversion Factors for Controlled Substances". Diversion Control Division. Drug Enforcement Administration, U.S. Department of Justice. Retrieved 8 October 2018.